Mealey's (October 10, 2016, 12:32 PM EDT) -- HERTFORSHIRE, U.K. — Mylan N.V. on Oct. 7 said it has agreed to pay $465 million to settle “questions” by the U.S. Justice Department and other government agencies that the company misclassified its EpiPen epinephrine autoinjector as a generic drug to pay the government less under the Medicaid Drug Rebate Program....